Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients

Solid Organ Transplant Rejection Clinical Trial

Official title: Intermediate Size Expanded Access for the Use of ExoFlo in the Treatment of Abdominal Solid Organ Transplant Patients Who Are at Risk of Worsening Allograft Function With Conventional Immunosuppressive Therapy Alone

Status Available

Clinical Trial Summary

This Expanded Access Protocol will provide access to the IMP ExoFlo for patients who have severe or life-threatening abdominal solid organ transplant rejection or who are evaluated and determined to be at high risk of progression to severe or life-threatening condition related to rejection of an abdominal solid organ transplant, at risk of worsening allograft function, or at risk of complications from current immunosuppressive therapeutic regimens.

Clinical Trial Description

Objectives: The primary objective of this expanded access program is to evaluate safety and tolerability of ExoFlo in patients with graft inflammation, or worsening graft function, or evidence of rejection of an abdominal solid organ transplant despite conventional therapies. The secondary objective is to characterize the improvement seen in serum inflammatory markers and inflammation of solid abdominal organ. Endpoints: Primary Endpoint: Incidence of AEs or SAEs. Secondary Endpoint: Improvement seen in serum inflammatory markers and inflammation of solid abdominal organ. This could include improvements seen in the following transplant types: - Liver transplant: overall improved liver function, as seen by reduction in liver function test and improved albumin. - Small bowel transplant: decreased inflammation on biopsy - Pancreas: decreased amylase and lipase - Multivisceral: any of the above criteria Number of subjects: 20 Phase: Expanded Access Protocol ;

Related Conditions & MeSH terms

• Solid Organ Transplant Rejection

• NCT number: NCT05215288
• Study type: Expanded Access
• Source: Direct Biologics, LLC
• Contact: Bill Arana
• Phone: 1-800-791-1021
• Email: clinicalaffairs@directbiologics.com
• Status: Available